Arvand Haschemi

Arvand Haschemi

Auto-generated profile, based on publicly available information

Arvand Haschemi

Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Cell Metabolism
Verified
Journal Article
Open access
AHArvand Haschemi
Arvand Haschemi
PKPaul Kosma
Paul Kosma
LGLars Gille
Lars Gille
CECharles Evans
Charles Evans
CBCharles F. Burant
Charles F. Burant
OWOswald Wagner
Oswald Wagner
Immune cells are somewhat unique in that activation responses can alter quantitative phenotypes upwards of 100,000-fold. To date little is known about the metabolic adaptations necessary to mount such dramatic phenotypic shifts. Screening for novel regulators of macrophage activation, we found nonprotein kinases of glucose metabolism among the most enriched classes of candidate immune modulators. We find that one of these, the carbohydrate kinase-like protein CARKL, is rapidly downregulated in vitro and in vivo upon LPS stimulation in both mice and humans. Interestingly, CARKL catalyzes an orphan reaction in the pentose phosphate pathway, refocusing cellular metabolism to a high-redox state upon physiological or artificial downregulation. We find that CARKL-dependent metabolic reprogramming is required for proper M1- and M2-like macrophage polarization and uncover a rate-limiting requirement for appropriate glucose flux in macrophage polarization.

1 January 2010 in Cell
Verified
Journal Article
Closed access
JPJ. Andrew Pospisilik
J. Andrew Pospisilik
DSDaniel Schramek
Daniel Schramek
HSHarald Schnidar
Harald Schnidar
SCShane J.F. Cronin
Shane J.F. Cronin
NNNadine T. Nehme
Nadine T. Nehme
JPJosef M Penninger
Josef M Penninger

16 January 2017 in Nature Immunology
Verified
Journal Article
Open access
PDF file
MLMonika Linke
Monika Linke
HPHa Thi Thanh Pham
Ha Thi Thanh Pham
KKKarl Katholnig
Karl Katholnig
TSThomas Schnöller
Thomas Schnöller
AMAnne Miller
Anne Miller
TWThomas Weichhart
Thomas Weichhart
Macrophages are critical for granuloma formation, but the cell-intrinsic mechanisms remain unknown. Weichhart and colleagues demonstrate that chronic mTOR activity leads to macrophage-dependent granuloma formation, which may have relevance to sarcoidosis. The aggregation of hypertrophic macrophages constitutes the basis of all granulomatous diseases, such as tuberculosis or sarcoidosis, and is decisive for disease pathogenesis. However, macrophage-intrinsic pathways driving granuloma initiation and maintenance remain elusive. We found that activation of the metabolic checkpoint kinase mTORC1 in macrophages by deletion of the gene encoding tuberous sclerosis 2 (Tsc2) was sufficient to induce hypertrophy and proliferation, resulting in excessive granuloma formation in vivo. TSC2-deficient macrophages formed mTORC1-dependent granulomatous structures in vitro and showed constitutive proliferation that was mediated by the neo-expression of cyclin-dependent kinase 4 (CDK4). Moreover, mTORC1 promoted metabolic reprogramming via CDK4 toward increased glycolysis while simultaneously inhibiting NF-κB signaling and apoptosis. Inhibition of mTORC1 induced apoptosis and completely resolved granulomas in myeloid TSC2-deficient mice. In human sarcoidosis patients, mTORC1 activation, macrophage proliferation and glycolysis were identified as hallmarks that correlated with clinical disease progression. Collectively, TSC2 maintains macrophage quiescence and prevents mTORC1-dependent granulomatous disease with clinical implications for sarcoidosis.

22 November 2007 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
MBMartin Bilban
Martin Bilban
AHArvand Haschemi
Arvand Haschemi
BWBarbara Wegiel
Barbara Wegiel
BCBeek Y. Chin
Beek Y. Chin
OWOswald Wagner
Oswald Wagner
LOLeo E. Otterbein
Leo E. Otterbein

8 April 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CNCsörsz Nagy
Csörsz Nagy
AHArvand Haschemi
Arvand Haschemi
A process is a function of time; in immunometabolism this is reflected by the stepwise adaptation of metabolism to sustain the bio-energetic demand of an immune-response in its various states and shades. This perspective article starts by presenting an early attempt to investigate the physiology of inflammation, in order to illustrate one of the basic concepts of immunometabolism, wherein an adapted metabolism of infiltrating immune cells affects tissue function and inflammation. We then focus on the process of macrophage activation and aim to delineate the factor time within the current molecular context of metabolic-rewiring important for adapting primary carbohydrate metabolism. In the last section we will provide information on how the pentose phosphate pathway may be of importance to provide both, nucleotide precursors and redox-equivalents, and speculate how carbon-scrambling events in the non-oxidative pentose phosphate pathway might be regulated within cells by demand. We conclude that the adapted metabolism of inflammation is specific in respect to the effector-function and appears as a well-orchestrated event, dynamic by nature, and based on a functional interplay of signalling- and metabolic-pathways.

1 November 2017 in Cell Metabolism
Verified
Journal Article
Closed access
AMAnne Miller
Anne Miller
CNCsörsz Nagy
Csörsz Nagy
BKBernhard Knapp
Bernhard Knapp
JLJohannes Laengle
Johannes Laengle
EPElisabeth Ponweiser
Elisabeth Ponweiser
AHArvand Haschemi
Arvand Haschemi